ISRCTN12421382
Completed
N/A
A multi-centre randomised controlled trial to compare the clinical and cost effectiveness of Lee Silverman Voice Treatment versus standard NHS speech and language therapy versus control in Parkinson’s disease (PD COMM)
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Parkinson's disease
- Sponsor
- niversity of Birmingham
- Enrollment
- 388
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
2017 Protocol article in https://www.ncbi.nlm.nih.gov/pubmed/28851443 protocol 2020 Protocol article in https://pubmed.ncbi.nlm.nih.gov/32460885/ protocol (added 29/05/2020) 2024 Results article in https://pubmed.ncbi.nlm.nih.gov/38986549/ (added 11/07/2024)
Investigators
Eligibility Criteria
Inclusion Criteria
- •Current inclusion criteria as of 08/04/2019:
- •1\. People who have idiopathic PD defined by the UK PDS Brain Bank Criteria. These criteria are in standard use throughout the NHS in the UK and supported by the NICE guidelines
- •2\. Person with PD or carer report problems with their speech or voice when asked
- •Previous inclusion criteria:
- •1\. People who have idiopathic PD defined by the UK PDS Brain Bank Criteria. These criteria are in standard use throughout the NHS in the UK and supported by the NICE guidelines
- •2\. Person with PD or carer report problems with their speech or voice when asked
- •3\. Aged 18 years and over
Exclusion Criteria
- •Current participant exclusion criteria as of 08/04/2019:
- •1\. Dementia as usually defined clinically by the person with PD’s physician
- •2\. Evidence of laryngeal pathology including vocal nodules or a history of vocal strain or previous laryngeal surgery within their medical records or from discussions with client, as LSVT is not appropriate for this group
- •3\. Received SLT for PD speech or voice related problems in the past 2 years
- •NB: Individual involvement in the trial is 12 months, but participants randomised to the control group can be referred for SLT at the end of trial (e.g. after 12 months) or, if it becomes medically necessary during the trial (e.g. within 12 months of randomisation).
- •Previous participant exclusion criteria:
- •1\. Dementia as usually defined clinically by the person with PD’s physician
- •2\. Evidence of laryngeal pathology including vocal nodules or a history of vocal strain or previous laryngeal surgery within their medical records or from discussions with client, as LSVT is not appropriate for this group
- •3\. Received SLT for PD speech or voice related problems in the past 2 years
- •4\. The investigator is certain that the person with PD will not require SLT during the 12 months of the trial. Individual involvement in the trial is 12 months, but participants randomised to the deferred treatment group can be referred for therapy after 12 months
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
N/A
Comprehensive geriatric assessment in a HAH settingTopic: Primary Care, AgeingSubtopic: Other Primary Care, Ageing, AgeingDisease: All AgeingNot ApplicableISRCTN60477865niversity of Oxford1,055
Active, Not Recruiting
N/A
The BASIL-3 Trial: Balloon vs. Stenting in Severe Ischaemia of the Leg-3Severe limb ischaemia due to femoro-popliteal diseaseCirculatory SystemPeripheral vascular disease, unspecifiedISRCTN14469736niversity of Birmingham481
Completed
Phase 3
Speed of Increasing milk Feeds TrialISRCTN76463425niversity of Oxford (UK)2,804
Active, Not Recruiting
N/A
Scaphoid Waist Internal Fixation for Fractures Trial: A trial evaluating cast versus surgical fixation for fractures of the scaphoid waist in adultsMusculoskeletal trauma of the hand and wristMusculoskeletal DiseasesISRCTN67901257niversity Hospitals of Leicester NHS Trust (UK)439
Completed
N/A
The effect of acupuncture in the prevention and treatment of chemotherapy-induced nausea and vomiting in patients with advanced cancerChemotherapy-induced nausea and vomitingSigns and SymptomsNausea and vomitingISRCTN13287728Beijing Municipal Administration of Hospitals136